saxagliptin + metformin XR

**Saxagliptin + metformin XR** is an oral fixed-dose, extended-release antidiabetic combination marketed in the United States as **Kombiglyze XR**. It combines saxagliptin, a selective dipeptidyl peptidase-4 inhibitor that prolongs incretin activity and thereby increases glucose-dependent insulin secretion while reducing glucagon secretion, with extended-release metformin, a biguanide that primarily lowers hepatic glucose production and improves insulin sensitivity. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both components is appropriate. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/200678s030lbl.pdf))

Brand names

Kombiglyze XR

Other names

Onglyza + Glucophage XRsaxagliptin + metformin extended releasesaxagliptin + metformin hydrochloride extended-releasesaxagliptin + metformin XR